Walleye Capital LLC Tricida, Inc. Transaction History

Walleye Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$8.51 - $13.6 $429,397 - $686,228	-50,458 Reduced 20.2%	199,317 $2.09 Million
Q2 2022 Aug 08, 2022	SELL	$7.31 - $11.85 $499,265 - $809,343	-68,299 Reduced 21.47%	249,775 $2.42 Million
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $1.19 Million - $1.72 Million	161,646 Added 103.34%	318,074 $2.62 Million
Q4 2021 Mar 03, 2022	BUY	$4.19 - $9.56 $655,433 - $1.5 Million	156,428 New	156,428 $1.5 Million
Q3 2021 Nov 15, 2021	SELL	$3.56 - $4.64 $181,652 - $236,760	-51,026 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$3.95 - $5.41 $201,552 - $276,050	51,026 New	51,026 $220,000
Q4 2020 Feb 16, 2021	SELL	$4.37 - $9.46 $293,664 - $635,712	-67,200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.56 - $26.93 $575,232 - $1.81 Million	67,200 New	67,200 $609,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.